AMPA receptor positive allosteric modulators attenuate morphine tolerance and dependence

Xiaoyu Hu, Xuebi Tian, Xiao Guo, Ying He, Haijun Chen, Jia Zhou, Zaijie Jim Wang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Development of opioid tolerance and dependence hinders the use of opioids for the treatment of chronic pain. In searching for the mechanism and potential intervention for opioid tolerance and dependence, we studied the action of two positive allosteric modulators of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR PAMs). In mice treated with morphine (100 mg/kg, s.c.), acute morphine tolerance and dependence developed in 4–6 h. Treatment with aniracetam, a well-established AMPAR PAM, was able to completely prevent and reverse the development of acute antinociceptive tolerance to morphine. Partial, but significant, effects of aniracetam on acute morphine induced-physical dependence were also observed. Moreover, aniracetam significantly reversed the established morphine tolerance and dependence in a chronic model of morphine tolerance and dependence produced by intermittent morphine (10 mg/kg, s.c. for 5d). In addition, HJC0122, a new AMPAR PAM was found to have similar effects as aniracetam but with a higher potency. These previously undisclosed actions of AMPAR PAMs are intriguing and may shed lights on understanding the APMA signaling pathway in opioid addiction. Moreover, these data suggest that AMPAR PAMs may have utility in preventing and treating morphine tolerance and dependence.

Original languageEnglish (US)
Pages (from-to)50-58
Number of pages9
JournalNeuropharmacology
Volume137
DOIs
StatePublished - Jul 15 2018

Fingerprint

aniracetam
Morphine Dependence
AMPA Receptors
Morphine
Opioid Analgesics
Chronic Pain
Light
Acids
Therapeutics

Keywords

  • AMPA
  • Morphine
  • Opioid dependence
  • Opioid tolerance
  • Positive allosteric modulator

ASJC Scopus subject areas

  • Pharmacology
  • Cellular and Molecular Neuroscience

Cite this

AMPA receptor positive allosteric modulators attenuate morphine tolerance and dependence. / Hu, Xiaoyu; Tian, Xuebi; Guo, Xiao; He, Ying; Chen, Haijun; Zhou, Jia; Wang, Zaijie Jim.

In: Neuropharmacology, Vol. 137, 15.07.2018, p. 50-58.

Research output: Contribution to journalArticle

Hu, Xiaoyu ; Tian, Xuebi ; Guo, Xiao ; He, Ying ; Chen, Haijun ; Zhou, Jia ; Wang, Zaijie Jim. / AMPA receptor positive allosteric modulators attenuate morphine tolerance and dependence. In: Neuropharmacology. 2018 ; Vol. 137. pp. 50-58.
@article{9e6f921c101141e8ab9a003d67d16767,
title = "AMPA receptor positive allosteric modulators attenuate morphine tolerance and dependence",
abstract = "Development of opioid tolerance and dependence hinders the use of opioids for the treatment of chronic pain. In searching for the mechanism and potential intervention for opioid tolerance and dependence, we studied the action of two positive allosteric modulators of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR PAMs). In mice treated with morphine (100 mg/kg, s.c.), acute morphine tolerance and dependence developed in 4–6 h. Treatment with aniracetam, a well-established AMPAR PAM, was able to completely prevent and reverse the development of acute antinociceptive tolerance to morphine. Partial, but significant, effects of aniracetam on acute morphine induced-physical dependence were also observed. Moreover, aniracetam significantly reversed the established morphine tolerance and dependence in a chronic model of morphine tolerance and dependence produced by intermittent morphine (10 mg/kg, s.c. for 5d). In addition, HJC0122, a new AMPAR PAM was found to have similar effects as aniracetam but with a higher potency. These previously undisclosed actions of AMPAR PAMs are intriguing and may shed lights on understanding the APMA signaling pathway in opioid addiction. Moreover, these data suggest that AMPAR PAMs may have utility in preventing and treating morphine tolerance and dependence.",
keywords = "AMPA, Morphine, Opioid dependence, Opioid tolerance, Positive allosteric modulator",
author = "Xiaoyu Hu and Xuebi Tian and Xiao Guo and Ying He and Haijun Chen and Jia Zhou and Wang, {Zaijie Jim}",
year = "2018",
month = "7",
day = "15",
doi = "10.1016/j.neuropharm.2018.04.020",
language = "English (US)",
volume = "137",
pages = "50--58",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - AMPA receptor positive allosteric modulators attenuate morphine tolerance and dependence

AU - Hu, Xiaoyu

AU - Tian, Xuebi

AU - Guo, Xiao

AU - He, Ying

AU - Chen, Haijun

AU - Zhou, Jia

AU - Wang, Zaijie Jim

PY - 2018/7/15

Y1 - 2018/7/15

N2 - Development of opioid tolerance and dependence hinders the use of opioids for the treatment of chronic pain. In searching for the mechanism and potential intervention for opioid tolerance and dependence, we studied the action of two positive allosteric modulators of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR PAMs). In mice treated with morphine (100 mg/kg, s.c.), acute morphine tolerance and dependence developed in 4–6 h. Treatment with aniracetam, a well-established AMPAR PAM, was able to completely prevent and reverse the development of acute antinociceptive tolerance to morphine. Partial, but significant, effects of aniracetam on acute morphine induced-physical dependence were also observed. Moreover, aniracetam significantly reversed the established morphine tolerance and dependence in a chronic model of morphine tolerance and dependence produced by intermittent morphine (10 mg/kg, s.c. for 5d). In addition, HJC0122, a new AMPAR PAM was found to have similar effects as aniracetam but with a higher potency. These previously undisclosed actions of AMPAR PAMs are intriguing and may shed lights on understanding the APMA signaling pathway in opioid addiction. Moreover, these data suggest that AMPAR PAMs may have utility in preventing and treating morphine tolerance and dependence.

AB - Development of opioid tolerance and dependence hinders the use of opioids for the treatment of chronic pain. In searching for the mechanism and potential intervention for opioid tolerance and dependence, we studied the action of two positive allosteric modulators of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR PAMs). In mice treated with morphine (100 mg/kg, s.c.), acute morphine tolerance and dependence developed in 4–6 h. Treatment with aniracetam, a well-established AMPAR PAM, was able to completely prevent and reverse the development of acute antinociceptive tolerance to morphine. Partial, but significant, effects of aniracetam on acute morphine induced-physical dependence were also observed. Moreover, aniracetam significantly reversed the established morphine tolerance and dependence in a chronic model of morphine tolerance and dependence produced by intermittent morphine (10 mg/kg, s.c. for 5d). In addition, HJC0122, a new AMPAR PAM was found to have similar effects as aniracetam but with a higher potency. These previously undisclosed actions of AMPAR PAMs are intriguing and may shed lights on understanding the APMA signaling pathway in opioid addiction. Moreover, these data suggest that AMPAR PAMs may have utility in preventing and treating morphine tolerance and dependence.

KW - AMPA

KW - Morphine

KW - Opioid dependence

KW - Opioid tolerance

KW - Positive allosteric modulator

UR - http://www.scopus.com/inward/record.url?scp=85048580363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048580363&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2018.04.020

DO - 10.1016/j.neuropharm.2018.04.020

M3 - Article

VL - 137

SP - 50

EP - 58

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

ER -